EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)
NCT: NCT06808880 · RECRUITING
Brief Summary
The purpose of this research is to develop and validate a single gene Non-Invasive Prenatal Test. The development of this investigational single-gene noninvasive prenatal testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy (SMA), Sickle cell disease, alpha thalassemia (a-thalassemia) and beta thalassemia (b-thalassemia) could provide information about the possibility that a child will be born with a serious health condition, in some cases in the absence of reproductive partner screening. In order to develop a test for this purpose, investigators will collect blood samples and medical information from pregnant women who have pregnancies at higher risk for single gene disorders, such as those who are carriers for these conditions or affected by these conditions themselves, medical data from their reproductive partners in some cases, and either genetic testing results or a cheek swab sample from the newborn(s).
Frequently Asked Questions
What is EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)?
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) is a clinical trial registered under NCT06808880. Current status: RECRUITING.
What is the status of NCT06808880?
The current status of NCT06808880 (EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)) is: RECRUITING.
When did EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) start?
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) started on 2024-01-25.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.